Healthcare
Vaxxinity, Inc.(VAXX)
Live Price
Offline$0.015
+14900.00% today
Window Change
+0.00%
Window
Jun 20, 2025 โ May 15, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +99.9%
- Dividend Yield
- 0.0%
Coverage: 228 bars ยท Jun 20, 2025 โ May 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vaxxinity, Inc. (VAXX) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and up 0.0% across the available one-year price window (Jun 20, 2025 โ May 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +99.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +99.9%, free cash flow -0.4% with operating margin 0.0% and ROIC -203.7%. Stock Foundry combines VAXX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +99.9%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -49.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +0.0% | โ | โ |
2026 Mar 26, 2026 | โ | +900.0% | -99.0% | -99.0% |
2025 Jun 5, 2025 | โ | +49900.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VAXX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VAXX Max Drawdown
-100.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VAXX and SPY.
Company Overview
Vaxxinity, Inc.
Other OTC
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.
- Leadership
- Mei Mei Hu
- IPO Date
- Nov 11, 2021
- Employees
- 57
- Street Address
- 1717 Main Street
- Mailing
- Dallas, TX, 75201
- Region
- Dallas, TX, US
- Reporting Currency
- USD
- Investor Line
- 254 244 5739
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 0.0
Growth
- Revenue
- 0.0%
- EPS
- +99.9%
- Free Cash Flow
- -0.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -0.2%
- ROIC
- -203.7%
Balance Sheet
- Debt/Equity
- 1.13
- Current Ratio
- 1.89
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.